Fetal Growth Restriction / SGA
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
A small estimated fetal size can reflect constitutional smallness or growth restriction. The clinical task is to assess growth trajectory, placental function and the wider pregnancy picture.
Assessment & interpretation
- Review dating, maternal risks, previous fetal-growth history and serial measurements.
- Use appropriate ultrasound assessment of growth, amniotic fluid and umbilical-artery Doppler; additional investigations depend on how early and how severely growth is affected.
Decisions that change management
- Arrange a surveillance plan with intervals and escalation criteria suited to the findings.
- Timing and mode of birth depend on fetal wellbeing, gestation and the balance between remaining in utero and prematurity; a percentile alone is not the entire decision.
- Maternal hypertension and other placental-disease features require concurrent assessment.
Follow-up & safety-netting
- Explain how to seek help for reduced movements, including between scheduled scans.
- Before planned preterm birth, discuss neonatal support and indicated antenatal treatment.
- Review newborn growth and the pregnancy outcome, and record what surveillance may be needed next pregnancy.
Clinical pitfalls
- Growth and Doppler results answer different questions. A single reassuring measurement should not erase a concerning trend or new maternal or fetal symptoms.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Abnormal/worsening fetal assessment, concerning Doppler findings, reduced movements, maternal hypertension or another complication may require admission and delivery planning.
When clinic, day care or home care may be suitable
- Selected stable FGR/SGA can be followed with a written schedule of growth, Doppler and other fetal surveillance and a planned birth date.
Before going home
- The specialist team has reviewed current growth/Doppler/fetal wellbeing and documented why the surveillance interval and location are safe.
- The patient has reliable access to the next test and urgent assessment; do not discharge with only a generic repeat scan in a few weeks.
Discharge medicines and treatment changes
- Record any antenatal steroid/neuroprotection course and remaining appointments; no unproven home drug is prescribed merely to increase fetal growth.
Tests, pending results and their reviewer
- Give exact scan/Doppler/CTG dates according to the diagnosed severity and gestation, plus the responsible reviewer.
Home care and counselling
- Explain reduced-movement reporting and the circumstances that would bring birth forward.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
At the booked specialist surveillance contacts | Review fetal and maternal findings and update timing/place of birth. |
Immediately for reduced movements/new symptoms | Reassess rather than waiting for the next scan. |
Return urgently
- Reduced/absent movements, bleeding, fluid loss, severe headache/visual symptoms or abdominal pain requires prompt maternity assessment.
Open the complete discharge checklist →
Treatment
① Immediate stabilization — first minutes
Not acute unless CTG pathological -> birth pathway.
③ First-line treatment & drug regimens
- LATE-ONSET FGR (>=32 wks): surveillance 2x weekly (CTG+UA); DELIVER ~37 wks when SGA with risk factors (NICE-style), earlier on deterioration
- EARLY-ONSET (<32 wks): intensive pathway - steroids complete if birth likely, MgSO4 <30-32, deliver on DV abnormality/reversed AEDF/CTG loss; expectancy only in tertiary centres with daily review
- Aspirin next-pregnancy prevention discussion; treat maternal disease aggressively
- Imminent preterm birth within the guideline gestational window; do not delay urgent maternal/fetal delivery
- NICE offers at 24+0–33+6 weeks, considers 34+0–35+6; individual discussion at 22+0–23+6. Repeat: <34 weeks, prior course >7 days ago and very high risk of birth in 48 h.
- Glucose monitoring and an insulin-adjustment plan in diabetes; assess infection and timing of birth
④ Drug treatment detail (2 agents)
- Indication: Alternative fetal-lung-maturation course when appropriate
- Maternal glucose, infection assessment and birth timing; diabetes team plan
- Indication: Imminent preterm birth: NICE offers at 24+0–29+6 weeks and considers at 30+0–33+6 weeks; discuss 23+0–23+6 individually
- Record pulse, BP, respiratory rate and tendon reflexes at least every 4 h; more often if oliguria or renal impairment
Definitive treatment
BIRTH remains the only definitive therapy once fetus outgrows placental support.
Monitoring
| Severity band | Surveillance |
|---|---|
SGA, normal Dopplers | Growth q2-3 wks + UA q1-2 wks + CTG weekly-ish per unit |
AEDF present | Hospital-based: UA/MCA/DV 2-3x weekly + daily CTG |
REDF/DV absent-flow | Daily assessment; delivery decision imminent |
Response assessment
- Stable Doppler trends; growth continuing along its curve
Treatment failure
- Deterioration cascade -> escalate frequency then deliver
Escalation
- Early-onset severe FGR belongs in units with NICU + fetal-medicine expertise - transfer BEFORE crisis
⑮ Complications & their management
Stillbirth
Timely delivery is the preventable lever; document surveillance compliance
Neonatal hypoglycaemia/polycythaemia
Paediatric anticipation at birth
Post-treatment care
- Placental histology request
- Next-pregnancy aspirin ± LMWH (APS cases) planning
Diagnosis & assessment
- Absent/reversed end-diastolic flow in umbilical artery (EARLY-onset marker)
- Reduced variability/abnormal CTG
- MCA PI fall + DV abnormality (late decompensation)
- Maternal hypertension/proteinuria emerging alongside
Definition: SGA: EFW/AC below 10th customised centile. FGR: placenta-mediated failure to achieve growth potential (may be normal-size!). Early-onset (<32 wks) vs late-onset (>=32 wks) differ in surveillance/delivery logic.
Risk factors
Initial assessment
- Confirm dating accuracy first!
- Customised growth charting (inter-growth/WHO standards where applicable)
- UA Doppler + amniotic fluid; MCA PI from 26-28 wks context
- Screen maternal causes: BP panel, anaemia, infection history, substance use
- Classify: early vs late onset; SGA-with-normal-Doppler vs true FGR
Investigations
| Test | Looking for |
|---|---|
Umbilical artery PI trend | Core surveillance axis (q1-3 wks by severity) |
MCA PI | Brain-sparing sign in late-onset deterioration |
Ductus venosus + CTG (early-onset severe) | Timing decisions <32 wks |
Maternal panel + TORCH where indicated | Reversible/non-placental causes |
Principles & follow-up
Management principles
Sources (10)
2022-02 · checked 2026-08-23 · pending-verification
Open source ↗
Cited via RCOG GTG73 update note; direct PDF audit pending — flag
· checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for fgr. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 Oct…
· checked 2026-10-17 · verified-summary
Open source ↗
Recommendation 1.9/type-and-regimen evidence: IM dexamethasone or betamethasone total 24 mg; four 6 mg dexamethasone doses 12 hours apart or two 12 mg betamethasone doses 24 hours apart. NICE NG25 supplies gestational and repeat-course criteria.
20 November 2015 · updated 10 June 2022 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for ptl-threatened, ptl-established. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admi…
25 June 2019 · updated 17 April 2023 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for hdp-postpartum. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Targeted medication audit: Table…
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.